Skip to main content
Clinical Trials/IRCT20180620040164N52
IRCT20180620040164N52
Completed
未知

Bioequivalence study of empagliflozin 12.5 combined tablet with metformin 1000 mg of Daro Darman Pars company in comparison with the reference sample of Syngardi made by Boehringer company.

Darou darman Pars Co.0 sites24 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Darou darman Pars Co.
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Darou darman Pars Co.

Eligibility Criteria

Inclusion Criteria

  • Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18\.5 and 30 (inclusive), calculated as kg/m2\.
  • Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
  • Subjects with normal vital signs.
  • Subjects who agree with patient consent form.

Exclusion Criteria

  • Subjects with known allergy to the products tested.
  • History of diabetes or other endocrine diseases
  • moking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period.
  • A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials